What is LOPJLB’s current signal on PYPD?

LOPJLB’s latest quantitative signal on PolyPid Ltd. (PYPD) is SELL in a BEAR regime. Signals are updated daily.

What market regime is PYPD in?

PolyPid Ltd. (PYPD) is currently classified in the BEAR HMM market regime on LOPJLB.

PolyPid Ltd. (PYPD)

COMPARE

Healthcare · Biotechnology · NASDAQ · IL

$5.07+3.47%Close

SELLBEAR · day 5

RANGE

DATA 2026-10-09

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $52M
Beta: 1.38
P/E (TTM): -3.47

Short % float: 1.90%
Days to cover: 1.8
SI change: -3.2%

1W: -2.31%
1M: -1.74%

vs SPY 1W: -3.47%
vs SPY 1M: -4.74%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of…

Employees: 72
Headquarters: IL
Founded: 2020
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 10.2M
Float: 65.3%

polypid.com ↗

Key executives

Dikla Czaczkes Akselbrad — Chief Executive Officer & Director

Dalit Hazan — Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs

Ori Warshavsky — Chief Operating Officer - US

SEC filings

EDGAR · CIK 16118420 · PYPD

Analyst consensus

Buy

Bullish888.9%

Neutral111.1%

Bearish00.0%

L $12.00Avg $12.50H $13.00

Target$12.50+146.55%

Last$5.07

FAQ

What is LOPJLB’s current signal on PYPD?: LOPJLB’s latest quantitative signal on PolyPid Ltd. (PYPD) is SELL in a BEAR regime. Signals are updated daily.
What market regime is PYPD in?: PolyPid Ltd. (PYPD) is currently classified in the BEAR HMM market regime on LOPJLB.
What does PolyPid Ltd. (PYPD) do?: PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase I…

Key stats

Prediction markets

Company news

FAQ